Loading…
Biodexa Pharmaceuticals Plc is projected to rise to $3.63 by 2027, a +11% move from its current price of $3.28. BDRX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $3.08 | $3.28 | $3.50 | +0.04% |
| May 30 | $3.00 | $3.28 | $3.59 | +0.08% |
| May 31 | $2.94 | $3.28 | $3.67 | +0.12% |
| Jun 1 | $2.89 | $3.29 | $3.73 | +0.16% |
| Jun 2 | $2.85 | $3.29 | $3.79 | +0.20% |
| Jun 3 | $2.81 | $3.29 | $3.85 | +0.24% |
| Jun 4 | $2.78 | $3.29 | $3.90 | +0.28% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.78 | $3.29 | $3.90 | +0.28% |
| Week 2 | $2.60 | $3.30 | $4.19 | +0.57% |
| Week 3 | $2.47 | $3.31 | $4.44 | +0.85% |
| Week 4 | $2.36 | $3.32 | $4.66 | +1.14% |
| Week 5 | $2.28 | $3.33 | $4.86 | +1.43% |
| Week 6 | $2.20 | $3.34 | $5.05 | +1.72% |
| Week 7 | $2.14 | $3.35 | $5.24 | +2.00% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Biodexa Pharmaceuticals Plc is a clinical stage biopharmaceutical company focused on developing a pipeline of products for familial adenomatous polyposis, non-muscle invasive bladder cancer, Type 1 diabetes, and rare/orphan brain cancer.
Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTX240, for the treatment of gastrointestinal stromal tumors.
In addition, Biodexa offers drug delivery platforms, such as Q-Sphera, MidaSolve, and MidaCore. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
BDRX is Biodexa Pharmaceuticals Plc, a clinical stage healthcare company trading at $3.28 per share with a market capitalization of $2.45M and a 5461 rank.
The stock’s current price and market position reflect a micro-cap healthcare player with a focused pipeline and ongoing Phase I/II programs across multiple indications.
The forecast landscape shows a mix of neutral, bearish and bullish years, with longer horizon years turning bullish and delivering higher average prices (e.g., 2040 avg $6.53 and 2050 avg $6.41) after a near-term dip (2030 avg $2.77).
Overall, the long-run outlook features potential upside from the mid-to-late 2030s into 2050, balanced by near-term risk signals and uncertain catalysts.
A major floor 42.3% below — a decisive break under it would weaken the trend.
The nearest floor, 7.6% below — buyers have tended to step in here.
The nearest ceiling, 48.2% above — a clean break opens room to run.
A major ceiling 243.0% above — clearing it would confirm fresh momentum.
Key BDRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BDRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.23 | Buy | $3.26 | Buy |
| MA 10 | $3.28 | Sell | $3.34 | Sell |
| MA 20 | $3.54 | Sell | $3.45 | Sell |
| MA 50 | $3.51 | Sell | $4.23 | Sell |
| MA 100 | $5.67 | Sell | $8.56 | Sell |
| MA 200 | $17.60 | Sell | $324.17 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.91 | Neutral |
| Stoch RSI (14) | 14.46 | Buy |
| CCI (20) | -39.87 | Neutral |
| Williams %R (14) | -90.29 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | -22.82 | Sell |
| Bollinger %B (20,2) | 0.38 | Neutral |
| Stochastic %K (14) | 9.71 | Buy |
| TRIX (15) | -0.32 | Sell |
| Awesome (5,34) | -0.29 | Sell |
| Ultimate (7,14,28) | 42.41 | Neutral |
| Momentum (10) | -0.52 | Sell |
| Aroon Osc (25) | 16.00 | Buy |
| Hull MA (9) | 3.26 | Buy |
| ADX (14) | 15.18 | Neutral |
| ATR (14) | 0.19 | Info |
The 30-day technical picture is bearish, with RSI14 at 40.
The stock’s price action is influenced by notable distance between the 50-day simple moving average and the 200-day simple moving average, with SMA50 listed at $3.54 and SMA200 at $17.91. Support is at $3.03 and resistance at $4.86, framing the near-term trading range.
The 30-day range spans from $2.07 to $5.21, indicating volatility and a wide intramonth trading band. The annualized volatility sits at 100%, underscoring substantial price variability over the period.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.03 | $3.28 | $4.54 | 0% | Neutral | |
| $2.61 | $3.63 | $5.46 | +11% | Neutral | |
| $2.41 | $3.56 | $5.69 | +8% | Neutral | |
| $2.01 | $3.12 | $5.23 | -5% | Neutral | |
| $1.70 | $2.77 | $4.83 | -15% | Bearish | |
| $1.64 | $2.78 | $5.02 | -15% | Bearish | |
| $2.28 | $4.03 | $7.50 | +23% | Bullish | |
| $2.44 | $4.50 | $8.59 | +37% | Bullish | |
| $2.18 | $4.19 | $8.20 | +28% | Bullish | |
| $2.20 | $4.40 | $8.81 | +34% | Bullish | |
| $2.92 | $6.49 | $14.28 | +98% | Bullish | |
| $2.94 | $6.53 | $15.01 | +99% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $3.03 | $3.28 | $3.88 | +0.00% |
| June 2026 | $2.67 | $3.21 | $3.98 | -2.27% |
| July 2026 | $2.79 | $3.40 | $4.34 | +6.17% |
| August 2026 | $2.87 | $3.54 | $4.60 | +4.05% |
| September 2026 | $2.67 | $3.34 | $4.41 | -5.61% |
| October 2026 | $2.55 | $3.22 | $4.32 | -3.53% |
| November 2026 | $2.63 | $3.35 | $4.54 | +4.03% |
| December 2026 | $2.58 | $3.32 | $4.54 | -1.15% |
Click any year to see its month-by-month BDRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The BDRX price prediction for 2026 points to an average of $3.28 (low $3.03, high $4.54) — a potential gain of 0% on today's $3.28. A consolidation phase looks the most probable path here.
In 2027, BDRX is projected to trade between $2.61 and $5.46, averaging $3.63 — a potential gain of +11% from today's $3.28. That is up +11% on the projected 2026 average. Price action looks broadly range-bound.
Biodexa Pharmaceuticals Plc's 2028 outlook centres on $3.56, within a $2.41 to $5.69 range. That is -2% versus the projected 2027 average. That marks a +8% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, BDRX could reach as high as $5.23, with a base case around $3.12 and support toward $2.01 — roughly -5% from $3.28. Price action looks broadly range-bound.
Expect BDRX to range from $1.70 to $4.83 through 2030. The $2.77 average target implies a -15% move from current prices. That is -11% versus the projected 2029 average. Expect choppier, lower action through this leg of the cycle.
The BDRX price prediction for 2031 points to an average of $2.78 (low $1.64, high $5.02) — a potential decline of -15% on today's $3.28. A cyclical pullback looks likely — prices rarely move in a straight line.
In 2032, BDRX is projected to trade between $2.28 and $7.50, averaging $4.03 — a potential gain of +23% from today's $3.28. That is up +45% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Biodexa Pharmaceuticals Plc's 2033 outlook centres on $4.50, within a $2.44 to $8.59 range. That is up +12% on the projected 2032 average. That marks a +37% change versus current levels. Momentum favours further upside here.
By 2034, BDRX could reach as high as $8.20, with a base case around $4.19 and support toward $2.18 — roughly +28% from $3.28. Buyers look set to stay in control over this stretch.
Expect BDRX to range from $2.20 to $8.81 through 2035. The $4.40 average target implies a +34% move from current prices. That is up +5% on the projected 2034 average. Momentum favours further upside here.
The BDRX price prediction for 2040 points to an average of $6.49 (low $2.92, high $14.28) — a potential gain of +98% on today's $3.28. Buyers look set to stay in control over this stretch.
In 2050, BDRX is projected to trade between $2.94 and $15.01, averaging $6.53 — a potential gain of +99% from today's $3.28. That is up +1% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in BDRX today (≈ 304.878049 BDRX) could be worth
$1,989.91
+$989.91 (+99%) by 2050 · US Dollar
Based on the average projected BDRX price of $6.53 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BDRXwould be worth at today's price.
$1,000 invested in BDRX on May 27, 2025 (≈ 17.391304 BDRX) would be worth
$57.04
-$942.96 (-94.3%) today · 0.06× · US Dollar
Based on a BDRX entry price of $57.5 vs. today's $3.28.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.11 | $1,054.66 | +5.5% |
| 1 month ago | $3.32 | $987.95 | -1.2% |
| 3 months ago | $5.65 | $580.53 | -41.9% |
| 6 months ago | $22.65 | $144.81 | -85.5% |
| 1 year ago | $57.5 | $57.04 | -94.3% |
| All time (5.0y) ago | $3,800,000 | $0 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BDRX forecast.
$6.60 is within our bullish range by 2032, but above the base case.
Implied market cap at $6.60: $4.92M
The multi-year forecast shows 2026 with an average price of $3.28 and a neutral sentiment, extending into 2027 ($3.63 avg, ROI 10.8, neutral) and 2028 ($3.60 avg, ROI 9.7, neutral).
By 2030 the average is $2.77 with a min of $1.70 and a max of $4.84, and the ROI is -15.5% with a bearish sentiment, signaling a notable near-term downside risk.
From 2032 onward, the forecast turns bullish, with 2032 avg $4.00 and max $7.44 (ROI 21.9%, bullish), 2033 avg $4.50 and max $8.61 (ROI 37.3%, bullish), and 2034 avg $4.21 and max $8.25 (ROI 28.5%, bullish).
In 2035 the average is $4.36 and max $8.73 (ROI 32.8%, bullish). The longer horizon shows strong upside potential, with 2040 avg $6.53 and max $14.36 (ROI 99%, bullish) and 2050 avg $6.41 and max $14.75 (ROI 95.6%, bullish).
Tap a question to reveal the answer.
Forecast: min $1.70, avg $2.77, max $4.84; ROI -15.5; sentiment BEARISH.
Forecast shows Neutral sentiment in 2026, 2027, 2028, and 2029; Bearish in 2030; Neutral in 2031; Bullish from 2032 onward with higher potential, including 2040 avg $6.53 (ROI 99) and 2050 avg $6.41 (ROI 95.6). Not financial advice.
Yes, the forecast maxes at $14.36 in 2040 and $14.75 in 2050, indicating potential upside in the longer term.
Current price is $3.28 and market cap is $2.45M.
30-day range is $2.07 to $5.21.
Biodexa Pharmaceuticals Plc Community Discussion
0Share your Biodexa Pharmaceuticals Plc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.